Previous close | 8.32 |
Open | 7.40 |
Bid | 6.55 |
Ask | 8.15 |
Strike | 119.00 |
Expiry date | 2024-05-10 |
Day's range | 5.25 - 7.40 |
Contract range | N/A |
Volume | |
Open interest | 211 |
Moderna ( NASDAQ:MRNA ) First Quarter 2024 Results Key Financial Results Revenue: US$167.0m (down 91% from 1Q 2023...
Despite a significant revenue drop, Moderna showcases robust clinical progress and strategic collaborations.
Pharmaceutical stocks Novo Nordisk (NVO) and Moderna (MRNA) are trending in opposite directions following their earnings reports. Despite topping Wall Street's profit expectations, Novo Nordisk shares are sinking as the company fell short of estimates for its popular GLP-1 weight-loss drug, Wegovy. Meanwhile, Moderna is on the rise even after reporting first quarter losses. Moderna's growth is largely due to an uptick in coronavirus boosters and an expansion into the Brazillian market. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl